Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy

  • Technology appraisal guidance
  • TA992
  • Published: 

An appeal has been lodged for this appraisal, however it was rejected. Below are the papers related to the appeal.  

 

This page was last updated: